within Pharmacolibrary.Drugs.ATC.N;

model N07BC03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1.05,
    adminDuration  = 600,
    adminMass      = 0.04,
    adminCount     = 1,
    Vd             = 0.0036,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0028333333333333335,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Levacetylmethadol (LAAM) is a synthetic opioid used in the management of opioid dependence as a substitute therapy. It acts as a long-acting agonist at the mu-opioid receptor and is an analog of methadone. LAAM was previously approved for opioid dependence treatment, but its use has been discontinued in the U.S. and Europe due to safety concerns, primarily related to cardiac arrhythmias (QT prolongation).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for adult opioid-dependent patients, typical oral dosing, based on data from public domain literature reviews and regulatory documents. No recent original clinical PK studies with numeric compartmental parameters found.</p><h4>References</h4><ol><li><p>Walsh, SL, et al., &amp; Bigelow, GE (1998). Intravenous and oral l-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans. <i>The Journal of pharmacology and experimental therapeutics</i> 285(1) 71–82. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9535996/&quot;>https://pubmed.ncbi.nlm.nih.gov/9535996</a></p></li><li><p>Fraser, HF, et al., &amp; Yeh, SY (1980). Possible influence of opioid normetabolites on the onset, magnitude and quality of the opioid abstinence syndrome. <i>Drug and alcohol dependence</i> 5(4) 255–272. DOI:<a href=&quot;https://doi.org/10.1016/0376-8716(80)90002-2&quot;>10.1016/0376-8716(80)90002-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6989579/&quot;>https://pubmed.ncbi.nlm.nih.gov/6989579</a></p></li><li><p>Kharasch, ED, et al., &amp; Lalovic, B (2005). Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. <i>Clinical pharmacokinetics</i> 44(7) 731–751. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200544070-00005&quot;>10.2165/00003088-200544070-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15966756/&quot;>https://pubmed.ncbi.nlm.nih.gov/15966756</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07BC03;
